Industry Deep-Dive: Deep Learning Algorithms for Automated Ophthalmic Screening in Medical Institutions and Population Health Settings
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Artificial Intelligence Eye Screening System – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Artificial Intelligence Eye Screening System market, including market size, share, demand, industry development status, and forecasts for the next few years.
Core User Pain Point & Solution Direction: Ophthalmologists, endocrinologists, and public health officials face a critical screening challenge: diabetic retinopathy (DR) affects approximately 30-40% of diabetics (463 million adults with diabetes globally), but specialist ophthalmologist shortages prevent timely screening (<50% of diabetics receive annual eye exams). Age-related macular degeneration (AMD) and myopia also require regular monitoring. Artificial intelligence eye screening systems solve this through automated retinal image analysis. Recent advances in machine learning and computer vision have enabled AI-based software trained on millions of retinal photos to screen for disease with high accuracy (sensitivity 85-95%, specificity 85-95%), often matching or exceeding human performance. These systems make screening more convenient, enable large-scale population screening, and reduce screening costs (US5−20perAIscreenvs.US5−20perAIscreenvs.US 50-150 for ophthalmologist exam). For medical institutions, AI screening systems integrate into clinical workflow (fundus cameras, teleophthalmology platforms). For population health, AI enables community-based screening (pharmacies, primary care, mobile clinics).
Global Market Size & Growth Trajectory
The global market for Artificial Intelligence Eye Screening System was estimated to be worth US423millionin2025andisprojectedtoreachUS423millionin2025andisprojectedtoreachUS 27,280 million, growing at a CAGR of 82.6% from 2026 to 2032. Asia-Pacific is the largest market (approximately 48% share). In terms of product type, diabetic retinopathy is the largest segment (approximately 53% share). In terms of application, medical institutions account for approximately 62% of demand. Key players include Airdoc Technology, Digital Diagnostics, and Eyenuk, with the top three holding over 55% market share. Explosive growth is driven by regulatory approvals (FDA, CE mark, NMPA), reimbursement establishment (CPT codes for AI screening in US), and expanding applications beyond DR to AMD, glaucoma, myopia, and cardiovascular risk prediction.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5514006/artificial-intelligence-eye-screening-system
Market Share & Competitive Landscape
The market features a moderately fragmented landscape with pure-play AI ophthalmology companies:
- Airdoc Technology (China) – Global leader, approximately 25% market share. AI retinal screening platform, strong in China and Asia-Pacific. NMPA approved for DR and multiple conditions.
- Digital Diagnostics (formerly IDx) (US) – Approximately 18% share. IDx-DR (first FDA-approved autonomous AI for diabetic retinopathy, 2018), now expanded to other conditions. Strong in US market.
- Eyenuk (US) – Approximately 12% share. EyeArt AI system, FDA cleared for DR screening (2020). Strong in US and international.
- EyRIS (SELENA+) (Singapore) – Approximately 8% share. SELENA+ for DR and glaucoma, strong in Asia-Pacific.
- RetinaLyze, Optomed, Sibionics, Aeye Health, VUNO, Medimaging, Vistel, RETINA-AI Health – Regional and specialist players.
The top three (Airdoc, Digital Diagnostics, Eyenuk) account for approximately 55% of global market share.
Type Segmentation by Eye Condition
- Diabetic Retinopathy (53% share) – Largest segment, 80% CAGR. Screening for referable DR (moderate NPDR or worse, diabetic macular edema). AI algorithms detect microaneurysms, hemorrhages, exudates, and neovascularization. FDA-cleared autonomous systems (IDx-DR, EyeArt) provide diagnostic output without ophthalmologist interpretation. Growing T2DM prevalence drives demand.
- Age-Related Macular Degeneration (AMD) (18% share) – 85% CAGR. AI algorithms detect drusen, pigmentary changes, geographic atrophy, and exudative AMD. Used in retina clinics and screening for at-risk elderly populations.
- Myopia (12% share) – 90% CAGR. AI algorithms measure axial length, detect myopic maculopathy, and track progression. High demand in Asia (80-90% myopia prevalence in young adults in China, Taiwan, South Korea, Singapore).
- Others (17% share) – Glaucoma (cup-to-disc ratio, RNFL defects), cardiovascular risk prediction (hypertensive retinopathy, retinal vessel caliber, stroke risk), Alzheimer’s disease prediction (retinal biomarkers).
Application Segmentation
- Medical Institutions (62% share) – Largest segment. Ophthalmology clinics, endocrinology clinics, primary care practices, hospitals. Integrated with fundus cameras, EMR workflows. AI improves screening efficiency (reduces specialist time for normal cases), identifies referable cases for ophthalmologist review.
- Great Health Scene (38% share) – Community-based screening: pharmacies (CVS, Walgreens), optical shops (LensCrafters), retail clinics, workplace wellness programs, mobile screening vans, public health campaigns (World Diabetes Day). Lower cost, accessible, reduces barriers to screening.
Technical Deep-Dive: AI Algorithm Performance and Regulatory Pathways
| Condition | AI System | Sensitivity | Specificity | AUC | Regulatory Status |
|---|---|---|---|---|---|
| Referable DR | IDx-DR (Digital Diagnostics) | 87% | 90% | 0.95-0.97 | FDA De Novo (2018), CE mark |
| Referable DR | EyeArt (Eyenuk) | 96% | 95% | 0.98 | FDA 510(k) (2020), CE mark |
| Referable DR | Airdoc | 91% | 93% | 0.96 | NMPA (2020) |
| AMD | SELENA+ (EyRIS) | 88% | 91% | 0.95 | CE mark, FDA pending |
| Myopia | Airdoc | 85-90% | 85-90% | 0.92-0.94 | NMPA (2021) |
Regulatory pathway: Autonomous AI (provides diagnosis without clinician interpretation) requires FDA De Novo or PMA (Digital Diagnostics IDx-DR). Non-autonomous AI (provides decision support, clinician reviews) requires FDA 510(k) clearance. Both require prospective clinical trials (multi-center, diverse populations).
Recent Regulatory and Reimbursement Breakthroughs (2024-2025)
- FDA clearances expanding: Airdoc received FDA 510(k) for DR screening (2024), entering US market. VUNO, EyRIS SELENA+ FDA submissions pending.
- Reimbursement: CMS (US Centers for Medicare & Medicaid Services) established CPT codes for AI-based retinopathy screening (92229, autonomous AI) reimbursing approximately US$ 45-50 per screening. Commercial payers (UnitedHealthcare, Anthem, Cigna, Aetna) following. Reimbursement accelerates adoption (fee-for-service) and justifies technology investment.
- UK NHS: AI for DR screening rolled out in select regions (NHS England AI Award, 2023-2025). UK has national diabetic eye screening program (DESP) covering 2.8 million diabetics annually. AI reduces human grader workload, addresses labor shortages.
Typical User Case (Q2 2025) – A US primary care practice (15 physicians, 4,000 diabetic patients) implemented Digital Diagnostics IDx-DR AI screening system (fundus camera + AI software). Process: medical assistant captures retinal images (2 minutes), AI provides result (normal/referable DR/warning). Normal patients (70-80%) received documentation of normal exam, no ophthalmology referral (saving specialist visits). Referable DR patients (20-30%) referred to ophthalmology. Results: Annual diabetic eye exam compliance increased from 35% to 78%, ophthalmology referrals reduced 40% (normal patients eliminated), practice generated US$ 180,000 in new screening revenue (CPT 92229 reimbursed). Patient satisfaction improved (no separate ophthalmology appointment for normal screening).
Exclusive Observation: Explosive Growth Projection Analysis
The 82.6% CAGR (US423M→US423M→US 27,280M, 2025-2032) reflects:
| Growth Driver | Impact | Assumption |
|---|---|---|
| Regulatory approvals (FDA, CE, NMPA, PMDA) | New markets opening | Most countries will approve by 2028 |
| Reimbursement establishment (CMS, private payers, national health systems) | Fee-for-service revenue | US, EU, China, Japan, Korea cover AI screening |
| AI screening replacing manual gradings | Labor cost savings, addresses shortage of ophthalmologists | 50-70% of routine screenings shifted to AI |
| Expanding applications (DR → AMD, glaucoma, myopia, cardiovascular risk) | Larger addressable population | >1 billion people eligible for eye screening annually |
| Global diabetes epidemic (463M adults, projected 700M by 2045) | Growing base of DR screening candidates | Annual DR screening recommended for all diabetics |
| Teleophthalmology and remote screening (pandemic legacy) | Decentralized care delivery | Pharmacies, primary care, retail clinics adopt AI |
Market skepticism: Some analysts question 80%+ CAGR sustainability beyond 2028-2030 (market saturation, reimbursement limits, competition, AI becoming commodity). However, current penetration is <5% of global diabetic eye screening market (US10−15billiontotaladdressablemarket).Evenat15−2010−15billiontotaladdressablemarket).Evenat15−20 2-3 billion by 2030. The US$ 27 billion projection assumes aggressive adoption and expansion into AMD, myopia, and cardiovascular screening.
Industry Segmentation: Software-as-a-Medical-Device (SaMD)
AI eye screening systems are Software-as-a-Medical-Device (SaMD) with deployment models:
| Model | Description | Examples | Regulatory | Revenue Model |
|---|---|---|---|---|
| Cloud-based (AI on vendor servers) | Images uploaded to cloud, AI processing, results returned | Airdoc Cloud, Digital Diagnostics Cloud | Requires data security (HIPAA, GDPR) | Per-screening fee (US$ 5-15) or subscription |
| On-premise (AI on local hardware) | AI software installed on local workstation/server | IDx-DR local, EyeArt Enterprise | Requires installation, IT support | Perpetual license (US$ 20-50k) + maintenance |
| Integrated (AI embedded in fundus camera) | AI chip or software pre-installed on fundus camera | Optomed Aurora AI, Airdoc integrated | Hardware + AI combo | Hardware sale (US$ 10-25k) + per-screening fee optional |
Cost structure (AI eye screening software, SaaS model, per-screening fee US$ 5-15):
| Component | Percentage |
|---|---|
| Algorithm development and training (deep learning, millions of labeled images) | 20-30% (amortized) |
| Cloud infrastructure (AWS/Azure, image storage, processing GPU) | 15-25% |
| Regulatory compliance (FDA, CE, NMPA, ISO 13485, HIPAA/GDPR) | 15-20% |
| Clinical validation (prospective trials, retrospective studies) | 10-15% |
| Sales and marketing (to clinics, hospitals, health systems) | 15-20% |
| Margin (SaaS vendor) | 20-30% (scaling to 40-50% at high volume) |
Additional Market Dynamics: The AI eye screening market faces challenges from (1) regulatory barriers (FDA De Novo requires clinical trials, 2-3 years, US$ 5-15M investment), (2) reimbursement uncertainty (CMS codes exist, but commercial payers vary, global payers limited), (3) algorithm generalizability (performance across different fundus camera models, ethnicities, disease severity), (4) integration with EMR and clinical workflow (requires API, IT support), (5) liability (AI diagnostic errors, missed disease). However, the combination of diabetes epidemic, ophthalmologist shortages (most countries have <5 ophthalmologists per 100,000 population), proven AI performance (sensitivity/specificity >90%), and regulatory/reimbursement progress positions the artificial intelligence eye screening system market for explosive growth (50-80% CAGR through 2030, then moderating) as AI becomes standard of care for diabetic retinopathy screening.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
